BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin - gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast. 2010;19:246-248. [PMID: 20227277 DOI: 10.1016/j.breast.2010.02.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Nhukeaw T, Temboot P, Hansongnern K, Ratanaphan A. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. BMC Cancer 2014;14:73. [PMID: 24507701 DOI: 10.1186/1471-2407-14-73] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
2 Liu M, Mo QG, Wei CY, Qin QH, Huang Z, He J. Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett 2013;5:983-91. [PMID: 23426861 DOI: 10.3892/ol.2012.1093] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
3 Song J, Zhong D, Qian W, Hou X, Chen JDZ. Short pulse gastric electrical stimulation for cisplatin-induced emesis in dogs: GES reduces cisplatin-induced emesis. Neurogastroenterology & Motility 2011;23:468-e178. [DOI: 10.1111/j.1365-2982.2011.01684.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
4 Celia C, Cosco D, Paolino D, Fresta M. Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. Expert Opin Drug Deliv 2011;8:1609-29. [PMID: 22077480 DOI: 10.1517/17425247.2011.632630] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
5 Chen Y, Guan Y, Wang J, Ma F, Luo Y, Chen S, Zhang P, Li Q, Cai R, Li Q, Mo H, Lan B, Chen X, Zhao W, Xu B, Fan Y. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. Int J Cancer 2020;147:3490-9. [PMID: 32588429 DOI: 10.1002/ijc.33175] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol 2011;11:7. [PMID: 21771338 DOI: 10.1186/1471-2210-11-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
7 Jin J, Zhang W, Ji W, Yang F, Guan X. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther 2017;18:369-78. [PMID: 28494179 DOI: 10.1080/15384047.2017.1323582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
8 Guo R, Long Y, Lu Z, Deng M, He P, Li M, He Q. Enhanced stability and efficacy of GEM-TOS prodrug by co-assembly with antimetastatic shell LMWH-TOS. Acta Pharm Sin B 2020;10:1977-88. [PMID: 33163348 DOI: 10.1016/j.apsb.2019.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
9 Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA. Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer 2012;12:322-30. [DOI: 10.1016/j.clbc.2012.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Wu K, Yang Q, Liu Y, Wu A, Yang Z. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol 2014;12:95. [PMID: 24731479 DOI: 10.1186/1477-7819-12-95] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
11 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E; European School of Oncology., European Society of Medical Oncology. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014;23:489-502. [PMID: 25244983 DOI: 10.1016/j.breast.2014.08.009] [Cited by in Crossref: 190] [Cited by in F6Publishing: 160] [Article Influence: 27.1] [Reference Citation Analysis]
12 Parisi M, Pelletier C, Cherepanov D, Broder MS. Outcomes research examining treatments, quality of life and costs in HER2 -negative and triple-negative metastatic breast cancer: a systematic literature review. Journal of Comparative Effectiveness Research 2018;7:67-83. [DOI: 10.2217/cer-2017-0027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Zhang J, Wang Z, Hu X, Wang B, Wang L, Yang W, Liu Y, Liu G, Di G, Hu Z, Wu J, Shao Z. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. Int J Cancer 2015;136:204-11. [PMID: 24824628 DOI: 10.1002/ijc.28966] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.9] [Reference Citation Analysis]
14 Wu J, Hicks C. Breast Cancer Type Classification Using Machine Learning. J Pers Med 2021;11:61. [PMID: 33498339 DOI: 10.3390/jpm11020061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
15 Liang S, Peng X, Li X, Yang P, Xie L, Li Y, Du C, Zhang G. Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin. Oncotarget 2015;6:1020-30. [PMID: 25544759 DOI: 10.18632/oncotarget.2741] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
16 Shamseddine AI, Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011;57:468-87. [PMID: 22248721 DOI: 10.1159/000334093] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
17 Pracharova J, Novohradsky V, Kostrhunova H, Štarha P, Trávníček Z, Kasparkova J, Brabec V. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells. Dalton Trans 2018;47:12197-208. [PMID: 30112527 DOI: 10.1039/c8dt02236d] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 6.3] [Reference Citation Analysis]
18 Zhang Z, Sun C, Zhang L, Chi X, Ji J, Gao X, Wang Y, Zhao Z, Liu L, Cao X, Yang Y, Mao W. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin. Biomedicine & Pharmacotherapy 2019;109:1541-6. [DOI: 10.1016/j.biopha.2018.11.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
19 Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A. Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO Open 2021;6:100019. [PMID: 33399082 DOI: 10.1016/j.esmoop.2020.100019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Purwanto I, Heriyanto DS, Widodo I, Hakimi M, Hardianti MS, Aryandono T, Haryana SM. MicroRNA-223 is Associated with Resistance Towards Platinum-based Chemotherapy and Worse Prognosis in Indonesian Triple-negative Breast Cancer Patients. Breast Cancer (Dove Med Press) 2021;13:1-7. [PMID: 33442288 DOI: 10.2147/BCTT.S291014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhang J, Lin M, Jin Y, Gu L, Li T, Yuan B, Wang B, Wang L, Zhang S, Cao J, Tao Z, Zhang J, Hu X. Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia. Breast Cancer Res Treat 2020;182:719-26. [PMID: 32524355 DOI: 10.1007/s10549-020-05730-2] [Reference Citation Analysis]
23 André F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 2012;23 Suppl 6:vi46-51. [PMID: 23012302 DOI: 10.1093/annonc/mds195] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 18.8] [Reference Citation Analysis]
24 Kim JS, Park IH, Lee KS, Ro J. Outcomes of palliative weekly low-dose gemcitabine-Cisplatin chemotherapy in anthracycline- and taxane- pretreated metastatic breast cancer patients. J Breast Cancer 2014;17:339-43. [PMID: 25548581 DOI: 10.4048/jbc.2014.17.4.339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
25 Stemmler HJ, diGioia D, Freier W, Tessen HW, Gitsch G, Jonat W, Brugger W, Kettner E, Abenhardt W, Tesch H, Hurtz HJ, Rösel S, Brudler O, Heinemann V. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Br J Cancer 2011;104:1071-8. [PMID: 21407218 DOI: 10.1038/bjc.2011.86] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
26 Baek DW, Park JY, Lee SJ, Chae YS. Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance. Yeungnam Univ J Med 2020;37:230-5. [PMID: 31962039 DOI: 10.12701/yujm.2019.00423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Tait DL, Blessing JA, Hoffman JS, Moore KN, Spirtos NM, Lachance JA, Rotmensch J, Miller DS. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2011;121:118-21. [PMID: 21159366 DOI: 10.1016/j.ygyno.2010.11.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
28 Golbaghi G, Castonguay A. Rationally Designed Ruthenium Complexes for Breast Cancer Therapy. Molecules 2020;25:E265. [PMID: 31936496 DOI: 10.3390/molecules25020265] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 19.0] [Reference Citation Analysis]
29 Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15:341-51. [PMID: 20632057 DOI: 10.1007/s10147-010-0106-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
30 O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP. Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014;32:3840-7. [PMID: 25349301 DOI: 10.1200/JCO.2014.55.2984] [Cited by in Crossref: 183] [Cited by in F6Publishing: 81] [Article Influence: 26.1] [Reference Citation Analysis]
31 Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R. Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat 2014;146:567-72. [PMID: 25001611 DOI: 10.1007/s10549-014-3033-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
32 Wu J, Mamidi TKK, Zhang L, Hicks C. Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer. Cancers (Basel) 2020;12:E1559. [PMID: 32545594 DOI: 10.3390/cancers12061559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
33 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
34 Rosvig LH, Langkjer ST, Knoop A, Jensen AB. Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer. Acta Oncol 2018;57:156-9. [PMID: 29202627 DOI: 10.1080/0284186X.2017.1407495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 2014;25:1871-88. [PMID: 25234545 DOI: 10.1093/annonc/mdu385] [Cited by in Crossref: 252] [Cited by in F6Publishing: 224] [Article Influence: 36.0] [Reference Citation Analysis]
36 Awada A, Bondarenko I, Bonneterre J, Nowara E, Ferrero J, Bakshi A, Wilke C, Piccart M. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Annals of Oncology 2014;25:824-31. [DOI: 10.1093/annonc/mdu025] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 9.4] [Reference Citation Analysis]